Hyperphosphatemia Treatment Market Size, Share, Opportunities, and Trends Report Segmented By Product, Test Type, Distribution Channel, and Geography – Forecasts from 2025 to 2030

Description

Hyperphosphatemia Treatment Market Size:

Hyperphosphatemia Treatment Market, with a 4.58% CAGR, is forecasted to rise from USD 2.113 billion in 2025 to USD 2.644 billion by 2030.

Hyperphosphatemia is a disorder when the body's phosphate levels are extremely low. Other factors that contribute to hyperphosphatemia include uncontrolled diabetes, excessive vitamin D levels, diabetic ketoacidosis, and low parathyroid hormone levels.

Hyperphosphatemia Treatment Market Growth Drivers:

• Opportunities for the hyperphosphatemia treatment market to increase

The incidence of chronic illnesses is rising, as is the number of elderly people, which are two key reasons for the hyperphosphatemia treatment market growth. However, the FDA's strict rules and the rise in pharmacological adverse effects for treating hyperphosphatemia might restrain market expansion. In addition, the market is anticipated to benefit financially from the tremendous potential of emerging economies like Brazil, South Africa, China, India, and others that have not yet reached their full potential.

• An increasing number of people on dialysis

One of the main reasons driving the hyperphosphatemia treatment market growth is the rise in chronic renal diseases on a global scale. The prevalence of CKD is growing tremendously and will continue to increase in the future. According to data released by the American Kidney Fund, Americans with renal disease are 37 million. American citizens with renal failure number about 807,000. The prevalence of kidney illness is rising alarmingly. 15% of American adults are now affected, which amounts to more than 1 in 7. After a specific period, hyperphosphatemia was seen in the majority of dialysis patients. Thus, the rise in chronic renal illnesses is fueling the hyperphosphatemia treatment industry expansion.

• Advancements in drug development

The advancement of research and treatment strategies is predicted to fuel the global hyperphosphatemia treatment market. For instance, it was discovered in 2022 that Lupin had released Sevelamer Hydrochloride pills (800 mg) in the USA, a drug intended to treat hyperphosphatemia in persons with chronic renal impairment. After gaining US FDA approval, the item had been made accessible. In contrast to those who got just tenapanor or only phosphate binders, maintenance dialysis patients with chronic renal failure who received a combination treatment of tenapanor and phosphate binders reported better control of hyperphosphatemia.

• Increasing investments in research

The expansion of the hyperphosphatemia treatment industry is also expected to be aided by rising research funding for several rare disorders, including X-linked hypophosphatemia (XLH), and high healthcare costs. For instance, Genome Canada and the Canadian Institutes for Health Research worked together to research rare genetic diseases using Next-Generation Sequencing (NGS) technology. As a result, this factor has caused the hyperphosphatemia treatment market to expand dramatically.

• Introduction of new hyperphosphatemia therapeutics by researchers

In CKD patients receiving dialysis, optimal phosphate management is exceedingly challenging to attain. Despite the amazing developments in dialysis treatments throughout the years, the capacity to manage phosphate levels in dialysis patients has not considerably improved. Additionally, phosphate binders have a variety of unfavourable side effects. In the future, non-phosphate binders like Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3), are anticipated to take the role of phosphate binders in the treatment of hyperphosphatemia, which will fuel the hyperphosphatemia treatment market growth.

• Increasing utilization in hospitals

Most hospital patients with renal illnesses require the usage of hyperphosphatemia medications. Patients who are on dialysis or those with chronic renal failure. The blood phosphate levels of these patients have increased because they are unable to eliminate the surplus quantities of phosphorus as a result of their kidneys not functioning correctly and are at risk of developing hospital-acquired hyperphosphatemia.

Hyperphosphatemia was present in these cases. The serum phosphate levels are decreased using medications. A prolonged period of untreated hospital-acquired hyperphosphatemia might raise the risk of mortality from serious cardiovascular problems such as congestive heart failure and death from arrhythmias.

Hyperphosphatemia Treatment Market Geographical Outlook:

• The market for treating hyperphosphatemia in North America is anticipated to expand quickly. 

North America is expected to have the highest hyperphosphatemia treatment market share because of the ageing population and a rise in chronic renal disease patients. Various product innovations in the region are also fueling the market. For instance, the biopharmaceutical business Ardelyx, Inc. has announced that three posters were exhibited during Kidney Week 2022, which was hosted in Orlando, Florida. The company was formed to identify, develop, and commercialize breakthrough first-in-class medicines to address large unmet medical needs. XPHOZAH (tenapanor) is a phosphate absorption inhibitor (PAI) created and discovered by Ardelyx for the treatment of chronic kidney disease (CKD) in dialysis patients.

Hyperphosphatemia Treatment Market Player Strategies:

Since numerous businesses have begun to enter the hyperphosphatemia treatment industry as a result of technical improvements, the level of competition has increased. For instance, Shield Therapeutics wants to create drugs to treat anaemia caused by iron deficiency and hyperphosphatemia. Feraccru, a product of the firm, is its best-selling item. In addition, the business has unveiled PT30, which provides hypoallergenic IV iron treatment.

Hyperphosphatemia Treatment Market Scope:

Hyperphosphatemia Treatment Market Segmentation

• By Product
  • Sevelamer
  • Calcium-based Phosphate Binders
  • Iron-based Phosphate Binders
  • Lanthanum Carbonate
  • Others
• By Test Type
  • Serum Phosphate Level Test
  • Serum Calcium Level Test
  • Blood Urea Nitrogen (BUN) Test
  • Serum Creatinine Test
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Others

Our Best-Performing Industry Reports:

• Healthcare Compliance Software Market
• Healthcare Data Storage Market
• Healthcare Fraud Analytics Market

Navigation:

• Hyperphosphatemia Treatment Market Size:
• Hyperphosphatemia Treatment Market Key Highlights:
• Hyperphosphatemia Treatment Market Growth Drivers:
• Hyperphosphatemia Treatment Market Geographical Outlook:
• Hyperphosphatemia Treatment Market Player Strategies:
• Hyperphosphatemia Treatment Market Scope:
• Our Best-Performing Industry Reports:

Table Of Contents

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HYPERPHOSPHATEMIA TREATMENT MARKET BY PRODUCT

5.1. Introduction

5.2. Sevelamer

5.3. Calcium-based Phosphate Binders

5.4. Iron-based Phosphate Binders

5.5. Lanthanum Carbonate

5.6. Others

6. HYPERPHOSPHATEMIA TREATMENT MARKET BY TEST TYPE

6.1. Introduction

6.2. Serum Phosphate Level Test

6.3. Serum Calcium Level Test

6.4. Blood Urea Nitrogen (BUN) Test

6.5. Serum Creatinine Test

6.6. Others

7. HYPERPHOSPHATEMIA TREATMENT MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacies

7.3. Retail Pharmacies

7.4. Online Pharmacies

8. HYPERPHOSPHATEMIA TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Therapy

8.2.2. By Route of Administration

8.2.3. By Indication

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Therapy

8.3.2. By Route of Administration

8.3.3. By Indication

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Therapy

8.4.2. By Route of Administration

8.4.3. By Indication

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Therapy

8.5.2. By Route of Administration

8.5.3. By Indication

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Therapy

8.6.2. By Route of Administration

8.6.3. By Indication

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5. Taiwan

8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Ardelyx, Inc.

10.2. Kissei Pharmaceutical Co., Ltd.

10.3. Astellas Pharma Inc.

10.4. Chugai Pharmaceutical Co., Ltd.

10.5. Sanofi S.A.

10.6. Akebia Therapeutics, Inc.

10.7. Fresenius Medical Care AG & Co. KGaA

10.8. Vifor Pharma AG

11. APPENDIX

11.1. Currency

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology

11.6. Abbreviations

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

Kissei

SRIASS

Clarivate

Ardelyx

MIMS

Astellas Pharma

Cigna

Chugai Pharm

Mayo Clinic

Related Reports